Women with epilepsy: Hormonal issues from menarche through menopause

Epilepsy and Behavior

Volumn 11, Issue 2, 2007, Pages 160-178

  Cramer, Joyce A ^a   Gordon, Jacki ^b   Schachter, Steven ^c   Devinsky, Orrin ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Epilepsy Therapy Development Project   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Menopause; Pregnancy; Reproductive health; Teratogenicity; Women's health

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLOMIFENE; CLONAZEPAM; CONTRACEPTIVE AGENT; ESTRADIOL; ESTROGEN; FOLLITROPIN; GABAPENTIN; GANAXOLONE; GONADORELIN; LAMOTRIGINE; LUBRICATING AGENT; LUTEINIZING HORMONE; NEUROSTEROID; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; PROGESTERONE; TESTOSTERONE; UNINDEXED DRUG; VALPROIC ACID;

AMENORRHEA; ANORGASMIA; ANTICONVULSANT ACTIVITY; ANXIETY; BONE DISEASE; BRAIN SURGERY; BREAKTHROUGH BLEEDING; BREAST FEEDING; CATAMENIAL EPILEPSY; CHILD PARENT RELATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONDOM; CONGENITAL MALFORMATION; CONTRACEPTION; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; EPILEPSY; FEMALE INFERTILITY; FRACTURE; HORMONAL REGULATION; HORMONE METABOLISM; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYSTERECTOMY; IMPOTENCE; INTRAUTERINE CONTRACEPTIVE DEVICE; LABOR; LIBIDO DISORDER; MATERNAL CARE; MENARCHE; MENOPAUSE; MENSTRUAL CYCLE; MONOTHERAPY; NONHUMAN; OLIGOMENORRHEA; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; OVULATION; PATHOPHYSIOLOGY; PATIENT COUNSELING; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; PRENATAL DIAGNOSIS; PROTEIN BINDING; PUERPERIUM; REPRODUCTIVE HEALTH; REVIEW; RISK REDUCTION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PSYCHOLOGY; SPONTANEOUS ABORTION; TEMPORAL LOBE EPILEPSY; TERATOGENESIS; TESTOSTERONE BLOOD LEVEL; UTERINE CERVIX CAP; VAGINAL DELIVERY; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; WOMEN'S HEALTH;

EID: 34548047879     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.03.007     Document Type: Review

References (230)

1. World Health Organization. Epilepsy: aetiology, epidemiology and prevalence. .
2. Dansky L.V., Andermann E., and Andermann F. Marriage and fertility in epileptic patients. Epilepsia 21 (1980) 261-271
3. Bilo L., Meo R., Valentine R., Di Carlo C., Striano S., and Nappi C. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrin Metab 86 (2001) 2950-2956
4. Scupf N., and Ottman R. Likelihood of pregnancy in individuals with idiopathic/cryptogenic epilepsy: social and biological influences. Epilepsia 35 (1994) 750-756
5. Scupf N., and Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia 37 (1996) 833-840
6. Webber M.P., Hauser W.A., Ottman R., and Anegers J.F. Fertility in persons with epilepsy: 1935-1974. Epilepsia 27 (1986) 746-752
7. Lofgren E., Mikkonen K., Tolonen U., et al. Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication. Epilepsy Behav 10 (2007) 77-83
8. Herzog A.G. Menstrual disorders in women with epilepsy. Neurology 66 6 Suppl. 3 (2006) S23-S28
9. Herzog A.G., and Fowler K.M. Sexual hormones and epilepsy: threat and opportunities. Curr Opin Neurol 18 (2005) 167-172
10. Blackstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 54 (1976) 321-347
11. Wallace H., Shorvon S., and Tallis R. Age specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 352 (1998) 1970-1973
12. Logothetis J., Harner R., Morrell F., and Torres F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology 9 (1959) 352-360
13. Herzog A.G. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 45 (1995) 1660-1662
14. Herzog A.G. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 52 (1999) 1917-1918
15. Veliskova J. Estrogens and epilepsy: why are we so excited?. Neuroscientist 13 (2007) 77-88
16. Veliskova J. The role of estrogens in seizures and epilepsy: the bad guys or the good guys?. Neuroscience 138 (2006) 837-844
17. Marcus E.M., Watson C.W., and Goldman P.L. Effects of steroids on cerebral electrical activity. Arch Neurol 15 (1966) 521-532
18. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., and Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232 (1986) 1004-1007
19. Wong M., and Moss R. Long-term and short-term electrophysiological effects of estrogen on the synaptic properties of hippocampal CA1 neurons. J Neurosci 12 (1992) 3217-3225
20. Wooley C.S., and Schwartzkroin P.A. Hormonal effects on the brain. Epilepsia 39 Suppl. 8 (1998) 52-58
21. Foldvary-Schaefer N., and Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 61 6, Suppl. 2 (2003) S2-S15
22. Drislane F.W., Coleman A.E., Schomer D.L., et al. Altered pulsatile secretion of lutenizing hormone in women with epilepsy. Neurology 44 (1994) 306-310
23. Bilo L., Meo R., Valentino R., Buscaino G.A., Striano S., and Nappi C. Abnormal patterns of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril 55 (1991) 705-711
24. Ruppenrecht R., Hauser C.A., Trapp T., and Holsboer F. Neurosteroids: molecular mechanisms of action and psychopharmacological significance. J Steroid Biochem Mol Biol 56 (1996) 1-6
25. Majewska M.D. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog Neurobiol 38 (1992) 375-379
26. Rodgers R.J., and Johnson N.J. Behaviorally selective effects of neuroactive steroids in plus-maze anxiety in mice. Pharmacol Biochem Behav 59 (1998) 221-232
27. Lonsdale D., and Burnham W.M. The anticonvulsant effects of progesterone and 5alpha-dihydroprogesterone on amygdala-kindled seizures in rats. Epilepsia 44 (2003) 1494-1499
28. Lonsdale D., Nylen K., and McIntyre Burnham W. The anticonvulsant effects of progesterone and its metabolites on amygdala-kindled seizures in male rats. Brain Res 1101 (2006) 110-116
29. Herzog A.G. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia 32 Suppl. 6 (1991) S27-S33
30. Herzog A.G. Hormonal changes in epilepsy. Epilepsia 36 (1995) 323-324
31. Pack A.M., and Morrell M.J. Treatment of women with epilepsy. Semin Neurol 22 (2002) 289-298
32. Morrell M.J., Flynn L., Seale C.G., et al. Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectr 6 (2001) 771-786
33. Zupanc M. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. Neurology 66 (2006) S37-S45
34. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16 (2002) 263-272
35. Tauboll E., Lundervold A., and Gjerstad L. Temporal distribution of seizures in epilepsy. Epilepsy Res 8 (1991) 153-165
36. Speroff L., Glass R.H., and Kase N.G. Clinical gynecologic endocrinology and infertility. 6th ed. (1999), Lippincott Williams & Wilkins, Philadelphia
37. Newmark N.E., and Penry J.K. Catamenial epilepsy: a review. Epilepsia 21 (1980) 281-300
38. Herzog A.G., Klein P., and Ransil B.J. Three patterns of catamenial epilepsy. Epilepsia 38 (1997) 1082-1088
39. Klein P., and Herzog A.G. Hormonal effects on epilepsy in women. Epilepsia Suppl. 8 (1998) S9-S16
40. Duncan S., Read C.L., and Brodie M.J. How common is catamenial epilepsy?. Epilepsia 34 (1993) 827-831
41. Herzog A.G., Harden C.L., Liporace J., et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 56 (2004) 431-434
42. Laidlaw J. Catamenial epilepsy. Lancet 271 (1956) 1235-1237
43. Rosciszewska D. Analysis of seizure dispersion during menstrual cycle in women with epilepsy. Mongr Neural Sci 5 (1980) 280-284
44. Shavit G., Lerman P., Korczyn A.D., Kivity S., Bechar M., and Gitter S. Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 34 (1984) 959-961
45. Gordon A. Epilepsy in its relation to menstrual periods. NY Med J 90 (1909) 733-735
46. Chia K.V., and Scarffe R.J. Catamenial epilepsy. Aust NZ J Obstet Gynaecol 33 (1993) 93-94
47. Poser C.M. Modification of therapy for exacerbation of seizures during menstruation [letter]. J Pediatr 84 (1974) 779-780
48. Ansell B., and Clarke E. Acetazolamide in treatment of epilepsy. Br Med J 1 (1956) 650-661
49. Ross I.P. Acetazolamide therapy in epilepsy. Lancet 2 (1958) 1308-1309
50. Lim L.L., Foldvary N., Mascha E., and Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia 42 (2001) 746-749
51. Feely M., Calvert R., and Gibson J. Clobazam in catamenial epilepsy: a model for evaluating anticonvulsants. Lancet 2 (1982) 71-73
52. Feely M., and Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry 47 (1984) 1279-1282
53. Hall S.M. Treatment of menstrual epilepsy with a progesterone-only oral contraceptive. Epilepsia 18 (1977) 235-236
54. Motta E., and Rosciszewska D. Progesterone therapy in epileptic women with catamenial seizures [abstract]. Epilepsia 36 Suppl. 3 (1995) 73
55. Reddy D.S. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 62 (2004) 99-118
56. Reddy D.S., and Rogawski M.A. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 294 (2000) 909-915
57. McAuley J.W., Moore J.L., Reeves A.L., Flyak J., Monaghan E.P., and Data J. A pilot study of the neurosteroid ganaxolone in catamenial epilepsy: clinical experience in two patients [abstract]. Epilepsia 42 (2001) 85
58. Morrell M.J. Sexual dysfunction in epilepsy. Epilepsia 32 (1991) S38-S45
59. Morrell M.J., and Guldner C.T. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia 37 (1996) 1204-1210
60. Harden C.L. Sexuality in women with epilepsy. Epilepsy Behav 7 Suppl. (2005) S2-S6
61. Bergen D., Daugherty S., and Eckenfels E. Reduction of sexual activities in females taking antiepileptic drugs. Psychopathology 25 (1992) 1-4
62. Herzog A.G. Psychoneuroendocrine aspects of temporolimbic epilepsy: Part II. Epilepsy and reproductive steroids. Psychosomatics 40 (1999) 102-108
63. Cummings L.N., Giudice L., and Morrell M.J. Ovulatory function in epilepsy. Epilepsia 36 (1995) 355-359
64. Morrell M.J., Giudice L., Flynn K.L., et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 52 (2002) 704-711
65. Isojarvi J.I.T., Laatikainen T.J., Pakarinen A.J., Juntunen K.T.S., and Myllyla V.V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329 (1993) 1383-1388
66. Isojarvi J.I.T. Reproductive dysfunction in women with epilepsy. Neurology 81 Suppl. 2 (2003) S27-S34
67. Morrell M.J. Sexuality in epilepsy. In: Engel J., and Pedley T.A. (Eds). Epilepsy: a comprehensive textbook (1997), Lippincott-Raven, New York 2021-2026
68. Morrell M.J., Sperling M.R., Stecker M., and Dichter M.A. Sexual dysfunction in partial epilepsy: a deficit in physiologic sexual arousal. Neurology 44 (1994) 243-247
69. Duncan S., Blacklaw J., Beastall G.H., and Brodie M.J. Sexual function in women with epilepsy. Epilepsia 38 (1997) 1074-1081
70. Morrell M.J., Flynn K.L., Done S., et al. Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav 6 (2005) 360-365
71. Gupta C., Odeman J., Santen R., et al. In vivo metabolism of progestins. J Clin Endocrinol Metab 48 (1979) 816-820
72. Gil-Nagel A., Lopez-Munoz F., Serratosa J.M., et al. Effect of lamotrigine on sexual function in patients with epilepsy. Seizure 15 (2006) 142-149
73. Laan E., van Lunsen R.H., Everaerd, et al. The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. J Womens Health Gender Based Med 11 (2002) 357-365
74. Klein P., Serje A., and Pezzullo J.C. Premature ovarian failure in women with epilepsy. Epilepsia 42 (2001) 1584-1589
75. Knochenhauser E.S., Key T.J., Kashar-Miller M., Waggoner W., Boots L.R., and Arriz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
76. Herzog A.G., and Schachter S.C. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia 42 (2001) 311-315
77. Bilo L., Meo R., Nappi C., et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 29 (1988) 612-619
78. Isojarvi J.I.T., Laatikainen T.J., Knip M., Pakarinen A.J., Juntunen K.S., and Myllyla V.V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39 (1996) 579-584
79. Isojarvi J.I.T., Tauboll E., Tapanainen J.S., et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 42 (2001) 305-310
80. Morrell M.J., Isojarvi J.I.T., Taylor A.E., et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 54 (2003) 189-199
81. Betts T., Yarrow H., Dutton N., Greenhill L., and Rolfe T. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 12 (2003) 323-329
82. Isojarvi J.I.T., Rattya J., Myllyla V.V., et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 43 (1998) 446-451
83. Stephen I.J., Kwan P., Shapiro D., Dominiczak M., and Brodie M.J. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 42 (2001) 1002-1006
84. Ferin M., Morrell M., Xiao E., et al. Endocrine and metabolic responses to long-term monotherapy with the antiepileptic drug valproate in the normally cycling rhesus monkey. J Clin Endocrinol Metab 88 (2003) 2908-2915
85. Fairgrieve S.D., Jackson M., Jonas P., et al. Population based, prospective study of the care of women with epilepsy in pregnancy. Br Med J 321 (2000) 674-675
86. Crawford P., and Hudson S. Understanding the information needs of women with epilepsy at different lifestages: results of the "Ideal World" survey. Seizure 12 (2003) 502-507
87. Seale C.G., Morrell M.J., Nelson L., et al. Analysis of prenatal and gestational care given to women with epilepsy. Neurology 51 (1998) 1039-1045
88. Crawford P., and Lee P. Gender difference in management of epilepsy-what women are hearing. Seizure 8 (1999) 135-139
89. Thorneycroft I., Klein P., and Simon J. The impact of antiepileptic drug therapy on steroidal contraceptive efficacy. Epilepsy Behav 9 (2006) 31-39
90. Mattson R.H., Cramer J.C., Darney P.D., and Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 256 (1986) 238-240
91. Commission on Genetics, Pregnancy, and the Child. International League Against Epilepsy. Guidelines for the care of women of childbearing age with epilepsy. Epilepsia 1993;34:588-9.
92. Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1998;51:944-8.
93. Erkkola R., and Landgren B.M. Role of progestins in contraception. Acta Obstet Gynecol Scand 84 (2005) 207-216
94. Speroff L., and Darney P.D. A clinical guide for contraception. 3rd ed. (2000), Lippincott Williams & Wilkins, Philadelphia
95. Crawford P., Chadwick D.J., Martin C., et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 30 (1990) 892-896
96. Doose D.R., Wang S.S., Padmanabhan M., et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44 (2003) 540-549
97. Sanno V., Glue P., Banfield C.R., et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 58 (1995) 523-531
98. Hachad H., Ragueneau-Majlessi I., and Levy R.H. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 24 (2002) 91-103
99. Coulam C.B., and Annegers J.F. Do anticonvulsants reduce the efficacy of oral contraceptives?. Epilepsia 20 (1979) 519-525
100. McAuley J.W., and Anderson G.D. Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet 41 (2002) 559-579
101. Patsalos P.N., and Perrucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2 (2003) 473-481
102. Park B.K., and Breckenridge A.M. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6 (1981) 1-24
103. Willmore L.F. Clinical pharmacology of new antiepileptic drugs. Neurology 55 (2000) S17-S24
104. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45 Suppl. 6 (2004) 13-18
105. Sabers A., Ohman I., and Tomson T. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsia 43 (2002) 47
106. Sabers A., Ohman I., Christensen J., and Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 61 (2003) 570-571
107. Christensen J., Petrenaite V., Atterma J., et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 48 (2007) 484-489
108. Sidhu J., Job S., and Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Pharmacol 61 (2006) 191-199
109. O'Brien M.D., and Gillebaud J. Contraception for women with epilepsy. Epilepsia 47 (2006) 1419-1422
110. Clinical Effectiveness Unit of the Faculty of Family Planning and Reproductive Health. Use of contraception outside terms of the product licence. J Fam Plann Reprod Health Care 2005;31:225-42.
111. Gilbert J.C., Scott A.C., Galloway D.B., et al. Ethosuxamide liver enzyme induction and d-glycaric acid excretion. Br J Clin Pharmacol 1 (1974) 249-252
112. Kurt H. Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia 25 (1984) S118-S131
113. Wilbur K., and Ensom M.H.H. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 38 (2000) 355-365
114. Garnett W.R. Clinical pharmacology of topiramate: a review. Epilepsia 41 Suppl. 1 (2000) 61-65
115. Krauss G.L., Brandt J., Campbell M., et al. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology 46 (1996) 1534-1539
116. Gupta S. Progestogen-only contraception: a review. Practitioner 249 (2005) 90-94
117. Pfizer Ltd. Depo-Provera, summary of product characteristics. 2004.
118. Depo-subQ provera 104™ [package insert]. New York: Pharmacia and Upjohn Co. 2005.
119. Shaarawy M., El-Mallah S., Seoudi S., Hassan M., and Mohsen I. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception 74 (2006) 297-302
120. MIRENA [package insert]. Montville, NJ: Berlex; 2003.
121. Bounds W., and Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 28 (2002) 78-80
122. Persona-A natural method of contraception that identifies the fertile days of a woman's cycle. .
123. Faculty of Family Planning and Reproductive Health. Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 2005;31:139-51.
124. Samren E.B., van Duijn C.M., Christiaens G.C., Hofman A., and Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46 (1999) 739-746
125. Schmidt D., Beck-Mannagetta G., and Janz D. The effect of pregnancy on the course of epilepsy: a prospective study. In: Janz D., Dam M., and Richens A. (Eds). Epilepsy, pregnancy, and the child (1982), Raven Press, New York 39-49
126. Hauser W.A., and Hesdorffer D.C. Risk factors. In: Hauser W.A., and Hesdorffer D.C. (Eds). Epilepsy: frequency, causes, and consequences (1990), Demos, New York 53-100
127. Tomson T., and Battino D. Teratogenicity of antiepileptic drugs: state of the art. Curr Opin Neurol 18 (2005) 135-140
128. Arpino C., Brescianini S., Robert E., et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE). Epilepsia 41 (2000) 1436-1443
129. Fried S., Kozer E., Nulman I., et al. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 27 (2004) 197-202
130. Knight A.H., and Rhind E.G. Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 16 (1975) 99-110
131. Yerby M.S. Pregnancy and epilepsy. Epilepsia 32 Suppl. 6 (1991) S51-S59
132. Pschirrer E.R. Seizure disorders in pregnancy. Obstet Gynecol Clin North Am 31 (2004) 373-384
133. Morrell M.J. Guidelines for the care of women with epilepsy. Neurology 51 5, Suppl. 4 (1998) S21-S27
134. Otani K. Risk factors for the increased seizure frequency during pregnancy and puerperium. Folia Psychiatr Neurol Jpn 39 (1985) 33-41
135. Tanganelli P., and Regesta G. Epilepsy, pregnancy and major birth anomalies: an Italian prospective, controlled study. Neurology 42 (1992) 89-93
136. Nei M., Saly S., and Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate. Neurology 51 (1998) 904-906
137. Morrell M.J. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 44 Suppl. 4 (2003) 11-20
138. Pennell P.B. The importance of monotherapy in pregnancy. Neurology 60 (2003) S31-S38
139. Yerby M.S. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 55 (2000) 21-31
140. Fonager K., Larsen H., Pederson L., and Sorensen H.T. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand 101 (2000) 289-294
141. Carhuapoma J.R., Tomlinson M.W., and Levine S.R. Neurologic diseases. In: James D.K., Steer P.J., Weiner C.P., and Gonic B. (Eds). High risk pregnancy: management options. 2nd ed. (1999), W.B. Saunders, London 803-836
142. Pennel P.B. Pregnancy in the woman with epilepsy: maternal and fetal outcomes. Semin Neurol 22 (2002) 299-307
143. MRC Vitamin Study Research Group. Prevention of neural tube defects; results of the Medical Research Council vitamin study. Lancet 1991;338:132-7.
144. Czeizel A.E., and Didas I. Prevention of the first occurrence of neural tube defects by periconceptual multivitamin supplementation. N Engl J Med 327 (1992) 1832-1835
145. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurology 1998;51:944-8.
146. O'Brien M.D., and Gilmour-White S.K. Management of epilepsy in women. Postgrad Med J 81 (2005) 278-285
147. Biale Y., and Lewenthal M. Effect of folic acid supplementation on congenital malformations due to anticonvulsant drugs. Eur J Obstet Gynecol Reprod Biol 18 (1984) 211-216
148. Verrotti A., Tana M., Pellicca P., Chiarelli F., and Latini G. Recent advances on neural tube defects with special reference to valproic acid. Endocr Metab Immune Disord Drug Targets 6 (2006) 25-31
149. Milunsky A., Jick H., Jick S.S., et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 262 (1989) 2847-2852
150. Yerby M. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 61 Suppl. 2 (2003) S23-S26
151. Hansen D.K., and Grafton T.F. Lack of attenuation of valproate induced effects by folinic acid in rat embryos in vitro. Teratology 52 (1995) 277-285
152. Seligmann H., Poasman I., Weller B., Schwartz M., and Prococimer M. Pheytoin-folic acid interaction: a lesson to be learned. Clin Neuropharmacol 22 (1999) 268-272
153. Dansky L.V., Rosenblatt D.S., and Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 42 4 Suppl. 5 (1992) 32-42
154. Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. ACOG educational bulletin. Seizure disorders in pregnancy. Number 231. Int J Gynaecol Obstet 1997;56:279-86.
155. Morrell M.J. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 44 Suppl. 4 (2003) 11-20
156. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural ube defects. MMWR 1992;41:1-7.
157. Kaneko S., Otani K., Fukushima Y., et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 29 (1988) 459-467
158. Koch S., Titze K., and Zimmerman R.B. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 40 (1999) 1237-1243
159. Adab N. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?. CNS Drugs 20 (2006) 791-800
160. DeHaan G.-J., Edelbroek P., Segers J., et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 63 (2004) 571-573
161. Mazzucchelli I., Onat F.Y., Ozcara C., et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 47 (2006) 504-509
162. Christensen J., Sabers A., and Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 67 (2006) 1497-1499
163. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006;66:354-60.
164. Samren E.B., van Duijin E.M., Koch S., et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38 (1997) 981-990
165. Holmes L.B., Harvey E.A., Coull B.A., et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 344 (2001) 1132-1138
166. Kaneko S., Battino D., Andermann E., et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 33 (1999) 145-158
167. Meador K.J., Baker G.A., Finnell R.H., et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 67 (2006) 407-412
168. Gaily E., Kantola-Sorsa E., Hiilesmaa V., et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62 (2004) 28-32
169. Adab N., Jacoby A., Smith D., and Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 70 (2001) 15-21
170. Adab N., Kini U., Vinten J., et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg 75 (2004) 1575-1583
171. Wyszynski D.F., Nambisan M., Surve T., et al. Increased rate of major malformation in offspring exposed to valproate during pregnancy. Neurology 64 (2005) 961-965
172. Vajda F.J., O'Brien T.J., Hitchcock A., et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian Register of Anti-epileptic drugs in Pregnancy. J Clin Neurosci 11 (2004) 854-858
173. Holmes L.B., Wyszynski D.F., Lieberman E., and AED Pregnancy Registry. The AED (antiepileptic drug) Pregnancy Registry: a 6-year experience. Arch Neurol 61 (2004) 673-678
174. Yerby M.S., Leavitt A., Erickson D.M., et al. Antiepileptics and the development of congenital anomalies. Neurology 42 Suppl. 5 (1992) 132-140
175. Hanson J.W., and Smith D.W. The fetal hydantoin syndrome. J Pediatr 87 (1975) 285-290
176. Rosa F.W. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 324 (1991) 674-677
177. Ohman I., Vitols S., and Thomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate during lactation. Epilepsia 41 (2000) 709-713
178. Genton P., Semah F., and Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf 29 (2006) 1-21
179. Zigler E. The definition and classification of mental retardation. Ups J Med Sci Suppl 44 (1987) 9-18
180. Vinten J., Adab N., Kini U., Gorry J., Gregg J., and Baker G.H. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64 (2005) 949-954
181. Kaaja E., Kaaja R., and Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 60 (2003) 575-579
182. Cunnington M., Tennis P., and and International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 64 (2005) 955-960
183. Hauser W.A., Tomson T., and Penovich P.E. Lamotrigine and the risk of malformations in pregnancy. Neurology 66 (2006) 153-154
184. Holmes L.B., Wyszynski D.F., Baldwin E.J., et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. Birth Defects Res (Part A) 76 (2006) 5
185. FDA Alert 9/2006. Lamotrigine (marketed as Lamictal) information. .
186. Kondo T., Kaneko S., Amano Y., and Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 37 (1996) 1242-1244
187. Ohtahara S., and Yamatoga Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 13 Suppl. 1 (2004) S50-S55
188. Hunt S., Craig J., Russell A., et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 67 (2006) 1876-1879
189. Pennell P. Pregnancy in women who have epilepsy. Neurol Clin 22 (2004) 799-820
190. Katz J.M., and Devinsky O. Primary generalized epilepsy: a risk factor for seizures in labour and delivery. Seizure 12 (2003) 217-219
191. Pilo C., Wide K., and Winbladh B. Pregnancy, delivery, and neonatal complications after treatment with antiepileptic drugs. Acta Obstet Gynecol Scand 85 (2006) 643-646
192. Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., and Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62 (2004) 292-295
193. Ito S. Drug therapy for breast-feeding women. N Engl J Med 343 (2000) 118-126
194. Nau H., Kuhnz W., Egger H.G., et al. Anticonvulsants during pregnancy and lactation: transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 7 (1982) 508-543
195. Liporace J., Kao A., and D'Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav 5 (2004) 102-105
196. Department of Economics and Social Affairs of the United Nations Secretariat. World population prospects: the 2004 revision. Vol. III. Analytical report. New York: United Nations; 2006. Available online at: .
197. Mitchell E.S., Woods N.E., and Mariella A. Three stages of menopausal transition from the Seattle Midlife Women's Health Study: toward a more precise definition. Menopause 7 (2000) 334-349
198. Harden C.L., Pulver M.C., Ravdin L., and Jacobs A.R. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 40 (1999) 1402-1407
199. Santoro M., Brown J.R., Adel T., and Skuurnick J.H. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 81 (1996) 1495-1501
200. Harden C.L., Koppel B.S., Herzog A.G., Nikolov B.G., and Hauser W.A. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology 61 (2003) 451-455
201. Harden C.L., Labar D., Koppel B., et al. Factors influencing the age of menopause in women with epilepsy. Epilepsia 43 Suppl. 7 (2002) 231-232
202. Abassi F., Krumholz A., Kittner S.J., and Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia 40 (1999) 205-210
203. McAuley J.W., Sapna S.J., Moore J.L., Peebles C.T., and Reeves A.L. Characterization and health risk assessment of postmenopausal women with epilepsy. Epilepsy Behav 1 (2000) 353-355
204. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results of the Women's Health Initiative randomized, controlled trial. JAMA 288 (2002) 321-333
205. Hom A.C., and Buterbaugh G.G. Estrogen alters the acquisition of seizures kindled by repeated amygdala stimulation or pentylenetetrazol administration in ovariectomized female rats. Epilepsia 27 (1986) 103-108
206. Harden C.L., Herzog A.G., Nikolov B.G., et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 47 (2006) 1447-1451
207. Harden C.L., Herzog A.G., Blagovest G., et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 47 (2006) 1147-1151
208. Tran T.A., Leppik I.E., Blesi K., et al. Lamotrigine clearance during pregnancy. Neurology 59 (2002) 251-255
209. Pennell P.B. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia 47 Suppl. 1 (2006) 46-53
210. Souverein P.D., Webb D.J., Petri H., Weil J., van Staa T.P., and Egberts A.C.G. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research database. Epilepsia 46 (2005) 304-310
211. Vestergaard P. Epilepsy, osteoporosis and fracture risk: a meta analysis. Acta Neurol Scand 112 (2005) 277-286
212. Persson H.B.I., Alberts K.A., Farahmand B.Y., and Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 43 (2002) 768-772
213. Vestergaard P., Rejnmark L., and Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 45 (2004) 1130-1137
214. Mattson R.H., and Gidal B.E. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 5 Suppl. 2 (2004) S36-S40
215. Souverein P.C., Webb D.J., Weil J.G., van Staa T.P., and Egberts A.C.G. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 66 (2006) 1318-1324
216. Pack A.M., Morrell M.J., Marcus R., et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 57 (2005) 252-257
217. Ensrud K.E., Walczak T.S., Blackwell T., Ensrud E.R., Bowman P.J., and Stone K.L. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62 (2004) 2051-2057
218. Harden C.L. Menopause and bone density issues for women with epilepsy. Neurology 61 Suppl. 2 (2003) S16-S22
219. Pack A. The association between antiepileptic drugs and bone disease. Epilepsy Curr 3 (2003) 91-95
220. Pack A.M., Olarte L.S., Morrell M.J., Flaster E., Resor S.R., and Shane E. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 4 (2003) 169-174
221. Ali I.I., Schuh L., Barkley G.L., and Gates J.R. Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav 5 (2004) 296-300
222. Feldkamp J., Becker A., Witte O.W., Scharff D., and Scherbaum W.A. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 108 (2000) 37-43
223. Kim S.H., Lee J.W., Choi K.-G., Chung H.W., and Lee H.W. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 10 (2007) 291-295
224. Mintzer S., Prashanthi B., Toguri J., and DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47 (2006) 510
225. Pediera J.D., Canal M.L., Carvajal J., et al. Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 30 (2000) 895-899
226. Mikati M.A., Dib L., Yamout B., et al. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 67 (2006) 2005-2014
227. Valmadrid C., Voorhees C., Litt B., and Schneyer C. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 58 (2001) 1369-1374
228. Drezner M.K. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 5 Suppl. 2 (2004) S41-S47
229. Heller H.J., and Sakhaee K. Anticonvulsant-induced bone disease: a plea for monitoring and treatment. Arch Neurol 58 (2001) 1352-1353
230. Elliott J.O., and Jacobson M.P. Bone loss in epilepsy: barriers to prevention, diagnosis, and treatment. Epilepsy Behav 8 (2006) 169-175